SUMMARY
Short sleep duration and circadian misalignment are hypothesized to causally contribute to health problems including obesity, diabetes, metabolic syndrome, heart disease, mood disorders, cognitive impairment, and accidents [1] [2] [3] [4] [5] [6] [7] . Here, we investigated the influence of morning circadian misalignment induced by an imposed short nighttime sleep schedule on impaired insulin sensitivity, a precursor to diabetes. Imposed short sleep duration resulted in morning wakefulness occurring during the biological night (i.e., circadian misalignment)-a time when endogenous melatonin levels were still high indicating the internal circadian clock was still promoting sleep and related functions. We show the longer melatonin levels remained high after wake time, insulin sensitivity worsened. Overall, we find a simulated 5-day work week of 5-hr-per-night sleep opportunities and ad libitum food intake resulted in 20% reduced oral and intravenous insulin sensitivity in otherwise healthy men and women. Reduced insulin sensitivity was compensated by an increased insulin response to glucose, which may reflect an initial physiological adaptation to maintain normal blood sugar [8] levels during sleep loss. Furthermore, we find that transitioning from the imposed short sleep schedule to 9-hr sleep opportunities for 3 days restored oral insulin sensitivity to baseline, but 5 days with 9-hr sleep opportunities was insufficient to restore intravenous insulin sensitivity to baseline. These findings indicate morning wakefulness and eating during the biological night is a novel mechanism by which short sleep duration contributes to metabolic dysregulation and suggests food intake during the biological night may contribute to other health problems associated with short sleep duration.
RESULTS AND DISCUSSION
The potential influence of altered circadian timing during short nighttime sleep schedules on negative metabolic consequences has not been investigated. Here, we investigated the influence of an imposed short sleep schedule and associated morning wakefulness occurring during the biological night (i.e., circadian misalignment) on oral and intravenous derived insulin sensitivity. All subjects slept %8.5 hr in the 9-hr condition suggesting 9 hr was an adequate opportunity for sleep. Condition order was not significant for the current analyses (all p > 0.11) and thus was removed from statistical models. However, to analyze the impact of adequate/recovery sleep following short sleep duration, primary outcomes for insulin sensitivity were analyzed separately by condition order.
Insulin Sensitivity from Oral and Intravenous Glucose Tolerance Tests
Findings from prior laboratory studies show insufficient sleep disrupts glucose metabolism [9] [10] [11] [12] [13] [14] . We show insulin sensitivity from oral glucose tolerance test (OGTT) derived Matsuda Insulin Sensitivity Index (OGTT-ISI; [1 / (mmol/l) 2 3 (pmol/l) 2 ]) decreased 21% in 5 hr versus baseline (p < 0.033) and 5-versus 9-hr conditions (p < 0.033; Figure 2A ) when controlling for positive or negative energy balance and body weight, with a medium effect size for condition (h 2 G = 0.18). Furthermore, subjects who completed 5 hr followed by 9 hr (Figure 1 ) showed 22% (p < 0.05) reduced OGTT-ISI in 5 hr versus baseline, and after 3 days of 9 hr, OGTT-ISI was similar to baseline ( Figure 2C ; p = 0.95). Subjects who started with 9 hr first showed a non-significant trend for 20% reduced OGTT-ISI in 5 hr versus baseline ( Figure 2C ; p = 0.06). Further, we likely did not have the statistical power to detect the small difference between 5-and 9-hr conditions in the group who completed 9 hr first (p = 0.11).
Intravenous glucose tolerance test (IVGTT)-derived insulin sensitivity (S I; [(mU/l) -1 3 min -1 ]) decreased by 39% (p < 0.033) and 20% (p < 0.033) after 5 days in 5 hr versus baseline and in 5-versus 9-hr conditions, respectively, and by 24% (p < 0.033) in 9 hr versus baseline ( Figure 2B ) when controlling for positive or negative energy balance and body weight with a medium effect size for condition (h 2 G = 0.18). Subjects who completed 5 hr followed by 9 hr (Figure 1 ) showed 51% (p < 0.05) and 32% (p < 0.05) decreased IVGTT-S I in 5 and 9 hr versus baseline, respectively, and thus did not show IVGTT-S I recovery to baseline levels after 5 days of the 9-hr condition (Figure 2D) . Subjects who completed 9 hr followed by 5 hr did not show statistically significant differences in IVGTT-S I between conditions (all p > 0.24). However, differences in IVGTT-S I among conditions were in the same direction as seen for subjects who completed 5 hr followed by 9 hr.
Associations between OGTT-ISI and IVGTT-S I , the Insulin Compensatory Response, and Circadian Misalignment It is well established that circadian misalignment leads to disrupted sleep [15] ; however, the influence of imposed short nighttime sleep schedules on circadian timing has largely been ignored. Findings from most short sleep duration studies in which circadian phase was examined show delayed circadian timing of melatonin onset [16] [17] [18] , whereas findings from one study showed a non-significant delay [13] . We found that melatonin levels were high for several hours after wake time in the 5-hr condition (Figure 3 ), indicating short sleep duration resulted in morning wakefulness occurring during the biological night, referred to hereafter as circadian misalignment. The longer melatonin levels remained high, insulin sensitivity was worse OGTT-ISI (p < 0.01; Figure 4A ) and IVGTT-S I (p < 0.05; Figure 4B ). Specifically, for every hour later the dim-light melatonin offset (DLMOff) occurred after wake time, representing the time when melatonin levels reduce back to low daytime levels, OGTT-ISI and IVGTT-S I decreased 0.25 and 0.29 units, respectively. Furthermore, the longer melatonin levels remained high after scheduled wake time, insulin secretion increased (OGTT-insulin area under the curve (AUC) [p < 0.01; Figure 4C ] and IVGTT-acute insulin response to glucose (AIRg) [p < 0.00001; Figure 4D] ). When condition was included as a fixed factor in the above statistical models, associations between the duration of high melatonin levels after wake time and worse OGTT-ISI (p = 0.06) and IVGTT-S I (p = 0.64) were no longer significant. This finding is not surprising since the duration of high melatonin levels after wake time was strongly dependent upon condition. Conversely, the associations between the duration of high melatonin levels after wake time and elevated insulin secretion remained significant (all p < 0.05) when condition was included as a fixed factor in the statistical model. These findings suggest, in addition to morning circadian misalignment, other physiological factors not analyzed here that change independent Example protocol showing one of the condition orders tested starting with 3 baseline days with 9-hr sleep opportunities followed by 5 days in the 5-hr condition and then 5 days in the 9-hr condition. Equal numbers of subjects completed 5-and 9-hr conditions first, in randomized order. Data represent recordings from the Actiwatch-L recorder, with activity denoted by black ticks and light exposure denoted in yellow. Data are double plotted with successive days plotted both next to and beneath each other; clock hour is indicated on the abscissa. Sleep timing was based on individual habitual sleep schedules. During the 5-hr insufficient sleep condition, sleep was restricted by delaying bedtime and advancing wake time by 2 hr each. Oral glucose tolerance tests were administered on study days 2 (baseline), 7, and 12 (green boxes). Intravenous glucose tolerance tests were administered on study days 4 (baseline), 9, and 14 (red boxes). Hourly blood samples were collected across 24 hr on study days 3 (baseline), 8, and 13 for assessment of insulin, glucose, and melatonin (24-hr circadian phase assessments). of condition may contribute to observed changes in insulin secretion.
Chronic metabolic disorders such as type 2 diabetes mellitus (T2DM) are epidemic [19] . Short sleep duration is considered an independent risk factor for T2DM [1, 4] and components of the metabolic syndrome [5] . Our findings demonstrate that decreased insulin sensitivity was associated with the degree of circadian misalignment that occurred during short sleep. As such, the longer melatonin levels were high after wake time, the worse was their insulin sensitivity. The 20% decrease in OGTT-ISI during short sleep is similar to the difference observed between lean individuals with normal versus impaired glucose tolerance [20] , and the 39% decrease in IVGTT-S i is similar to differences in insulin sensitivity observed between lean versus obese women [21] or middle-aged sedentary adults and improvements in insulin sensitivity after 6 months of aerobic exercise training [22] . Our findings have implications for research studies using the OGTT. This test is often performed in the morning with little consideration of participants awakening early from sleep and thus possibly being awake during their biological night while testing.
Our findings showing elevated OGTT early-phase insulin secretion, OGTT insulin AUC, and IVGTT-AIRg and C-peptide (Supplemental Information) indicate decreased insulin sensitivity and elevated insulin secretion during the imposed short sleep schedule. Additionally, higher OGTT-ISI was associated with lower OGTT-AUC across conditions (Supplemental Information) indicating b-cell compensation for reduced insulin sensitivity [8] . Since the disposition index (DI), a validated marker of T2DM risk, was similar across conditions, elevated insulin secretion was sufficient to compensate for reduced insulin sensitivity.
Thus, greater insulin levels likely reflect an initial physiological adaptation to maintain normal blood glucose levels during sleep loss. Progression to T2DM requires reduced insulin sensitivity and reduced insulin secretion. How long such compensation is maintained under sleep loss is unknown, but other models suggest that such physiology is not sustainable eventually leading to b-cell failure and diabetes [8] . Findings from most controlled laboratory studies using similar protocols show either a decrease [9] or no change [10, 11, 13] in insulin secretion during sleep restriction. Why we find a compensatory insulin response during sleep loss may be associated with methodological differences among studies. Specifically, in studies referenced above, IVGTTs were scheduled at specific clock hours beginning 3-4 hr after wake time during short sleep and 1 hr after wake time during adequate sleep conditions. Instead, we scheduled IVGTTs and OGTTs to begin 1 hr after wake time in all conditions (Figure 1) , consistent with the typical timing of breakfast [23] . Thus, our findings are likely translatable to ''real-world'' settings with food intake shortly after awakening. However, as in many other short sleep duration studies [9-11, 14, 17 , 18], we tested one short sleep condition composed of a delayed bedtime and advanced wake time by 2 hr each. Metabolic and circadian changes in additional models of short sleep should be tested (e.g., delaying bedtime [24] , advancing wake time, different sleep durations, early morning shift work). Of note, our findings are consistent with those from Klingenberg et al. [24] showing three nights of 4 hr time in bed resulted in elevated fasting insulin and postprandial C-peptide in response to a standardized breakfast consumed 1 hr after awakening. Thus, time awake before eating breakfast as well as eating during the biological night under imposed short sleep conditions may be factors influencing glucose regulation. Furthermore, in prior studies [9, 10, 13, 14, 24] , mostly or exclusively men were tested, and subjects were maintained under sedentary conditions and exposed to dim or unspecified lighting [9] [10] [11] 13] . We tested equal numbers of men and women and subjects completed two 20-min stair-stepping sessions per day to mimic energy expenditure associated with activities of daily living and were exposed to natural sunlight and typical room lighting during scheduled wakefulness, except on melatonin assessment days, to mimic ''real-world'' light exposure during the imposed short sleep duration studied.
Transitioning from a short sleep to an adequate/recovery sleep schedule restored OGTT-ISI, but not IVGTT-S I , to baseline levels ( Figures 2C and 2D ). Our findings are consistent with those from Killick et al. [25] showing improved OGTT derived insulin sensitivity after three nights of 10 hr time in bed in individuals regularly sleeping <6.5 hr per night on weeknights. Since IVGTT-S I did not recover in the current study with 5 days of 9 hr time in bed, this suggests more recovery sleep may be needed for complete restoration of IVGTT-S I versus OGTT-ISI. Furthermore, improved fasting insulin:glucose ratios [26, 27] and fasting QUICKI insulin sensitivity has been reported following recovery sleep/sleep extension [27] . The meal and OGTT findings are most relevant to understanding metabolic responses to food intake during short sleep schedules, as they incorporate intestinal responses. Our findings may also be relevant to late chronotypes who awaken at an earlier circadian time and thus may consume food during their biological night [28, 29] . Our findings showing recovery of OGTT-ISI but not IVGTT-S I with adequate sleep opportunities suggest the intestine (e.g., incretin axis and/or microbiota) may contribute, in part, to changes in insulin sensitivity following sleep loss as the IVGTT bypasses the gut. Future studies should consider assessing both oral and intravenous measures of glucose tolerance to understand recovery from short sleep duration, physiological factors mediating differences in metabolic responses to OGTT and IVGTT, and the effectiveness of sleep and circadian treatment strategies. Furthermore, a better understanding of the time course of recovery across days is needed as our findings suggest that the common phenomena of weekend recovery sleep may be insufficient to maintain metabolic health, at least for intravenous derived insulin sensitivity.
We used melatonin as a circadian phase marker with high levels representing the biological night; thus, our findings do not necessarily address direct effects of melatonin per se on insulin sensitivity or secretion [30, 31] , nor do they address the role of melatonin receptor polymorphisms (MTNR1B) on diabetes risk [32] . Our findings are consistent with models of circadian misalignment showing that eating or glucose infusion during the biological night is acutely associated with altered glucose metabolism and/or insulin sensitivity [33] [34] [35] [36] [37] . Additionally, findings from studies investigating the human plasma metabolome indicate circadian control of a range of metabolites linked to metabolic processes, further implicating circadian misalignment in metabolic dysregulation [38, 39] . Furthermore, findings indicate that social jetlag is associated with increased BMI [40] and being a later chronotype is associated with poorer glycemic control in diabetes patients [28] . Together, these findings indicate food intake during the biological night, when the human circadian system is not prepared for food intake, has negative metabolic consequences. Furthermore, the combination of short sleep duration and experimentally imposed circadian misalignment-simulating jet travel around the world and night shift work-show increased plasma glucose concentrations after a meal [36, 41] and reduced IVGTT-S I [13] , more than does short sleep duration alone. Our controlled Clinical Translational Research Center (CTRC) within-subject design permits strong conclusions about differences in insulin sensitivity across conditions. As melatonin was assessed on the day between OGTT and IVGTT assessments, and subjects were exposed to sunlight on OGTT and IVGTT test days, there could have been differences in circadian timing on insulin sensitivity test days. Future assessments of tissue-specific insulin sensitivity [14, 42] are needed to improve our mechanistic understanding of how short sleep duration and associated morning wakefulness and food intake during the biological night impacts glucose metabolism.
In summary, our findings highlight that short sleep can result in circadian misalignment, i.e., morning wakefulness during the biological night, and that the degree of circadian misalignment was associated with and likely contributes to metabolic dysregulation observed in response to nutrition intake during short sleep schedules. In addition to findings from others [9, [25] [26] [27] , our finding that obtaining 3 days of adequate sleep after 5 days of short sleep returned OGTT insulin sensitivity to baseline suggests large clinical trials are needed to determine whether sleep and circadian timing of food intake are non-pharmacologic, modifiable risk factors that can improve metabolic health. ]. AUC, area under the curve (mg/dl 3 min). AIRg, acute insulin response to glucose (mU 3 l -1 3 min).
DLMOff 25% , dim-light melatonin offset. p values for the associations can be found in the main text results.
Subjects
Sixteen healthy young adults (eight women), aged 22.4 (±4.8; SD) with normal BMI 22.9 (2.4), fasting glucose 81.9 mg/dl (12.7), and habitual sleep duration 8.3 hr (0.7) participated. After providing written informed consent, subjects underwent health screening consisting of medical, psychological, and sleep history, semi-structured clinical psychiatric interview, physical examination, complete blood count, and comprehensive metabolic panel, urine toxicology, 12-lead electrocardiogram, and polysomnographic sleep disorders screen. Based on these tests, subjects were deemed free of medical and psychological disorders. Inclusion criteria were 18-35 years old; BMI 18.5-24.9 kg/m 2 ; habitual nightly sleep >7 hr and <9.25 hr; low-moderate caffeine use (<500 mg/day); average alcohol use less than two drinks/day and less than five drinks/week; non-smokers. Subjects with low physical activity were studied to prevent detraining effects when living in the laboratory. Exclusion criteria were current or chronic medical/psychiatric conditions; pregnancy; shift work or dwelling below Denver altitude (1,600 m) within prior year; travel across greater than one time zone in 3 weeks prior to study; maximal lifetime BMI >27.5 kg/m 2 ; recent self-reported weight loss; abnormal eating patterns identified by registered dietician interview and three-item eating questionnaire [43] , and positive toxicology.
Protocol
Subjects discontinued caffeine and maintained consistent 9-hr-per-night sleep schedules at habitual times to ensure they were not sleep deprived the week prior to study [16] . During the 3 days prior to study, subjects were provided and consumed an energy balanced diet [16] , and exercise was proscribed. Urine toxicology and breath alcohol testing (Lifeloc Technologies Model FC10) verified drug-free status upon admission to the University of Colorado Hospital CTRC. Protocol events, including imposed wakefulness and sleep opportunities, were scheduled relative to the participant's habitual bed and wake time, as determined by pre-study monitoring. Following three inpatient baseline days with 9-hr-per-night sleep opportunities, subjects were studied in a crossover counterbalanced design with 9-hr-per-night adequate sleep (9-hr) and 5-hr-per-night short sleep duration (5-hr) conditions lasting 5 days each, to simulate a 5-day work week (Figure 1 ). Sleep was restricted by delaying bedtime and advancing wake time by 2 hr each. Our sleep suite allows room light and sunlight exposure during scheduled wakefulness and darkness during scheduled sleep [16] , thus simulating altered light exposure patterns during short sleep schedules within the safety of the laboratory. Energy balanced diets continued during baseline, whereas food intake was ad libitum during scheduled wakefulness of 5-and 9-hr conditions [16] . Findings showing shorter sleep duration, similar average light exposure, later circadian phase, increased 24-hr food intake and increased 24-hr energy expenditure in the 5-hr short sleep condition from this counterbalanced-crossover study ( Figure 1 ) have been reported [16] .
Insulin Sensitivity and Glucose Metabolism
OGTTs were administered under fasting conditions beginning 1 hr after scheduled awakening on day 2 (baseline), and days 7 and 12 (after 3 days of the 9-and 5-hr conditions; Figure 1 ). The primary OGTT outcome was Matsuda-ISI [44] . IVGTTs were administered under fasting conditions beginning 1 hr after scheduled awakening on study day 4 (baseline), and days 9 and 14 (after 5 days of the 9-and 5-hr conditions; Figure 1 ). The primary IVGTT outcome was minimal model S I [45] . The Supplemental Information provides secondary outcomes and detailed methods for OGTT and IVGTT. Plasma glucose and insulin 24 hr AUC were also assessed ( Figure 1 ; Supplemental Information).
Circadian Phase Assessment
Melatonin levels were assessed from hourly 24-hr blood samples on days 3, 8, and 13 in dim light (<8 lux) during scheduled wakefulness. High melatonin levels represent the biological night. Melatonin offset (DLMOff 25% ) was defined as the linear interpolated point in time at which melatonin levels fell below 25% of the fitted peak-to-trough amplitude of each individual's melatonin data as determined by a three-harmonics least-squares regression analysis [46] [47] [48] .
The circadian timing of DLMOff 25% was calculated as a circadian phase marker representing the end of the biological night [16, 46] . Further, we calculated the duration between the DLMOff 25% and wake time.
Statistics
Mixed-effects ANOVA with condition and condition order as fixed factors, subject as a random factor with weight and positive or negative energy balance [16] as covariates, was used to test for condition differences using Statistica (v.10.0; Statsoft). One-tailed dependent t tests with modified Bonferroni correction for multiple comparisons were used to test planned comparisons between conditions for our primary outcomes of insulin sensitivity; two-tailed dependent t tests were used for secondary planned outcomes. Linear mixed model analyses using R (v.3.1.2) was used to test associations between OGTT-ISI and insulin AUC, and IVGTT-S I, and AIRg with the circadian timing of the DLMOff 25% relative to scheduled wake time. The DLMOff 25% relative to wake time and condition order was entered as fixed factors, subject as a random factor, and weight and positive or negative energy balance as covariates. Integrated AUC analyses were performed using OriginPro (v.92E). Effect size analyses were calculated using generalized eta squared (h 2 G; Supplemental Information).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, three figures, and one table and can be found with this article online at http://dx.doi.org/10.1016/j.cub.2015.10.011.
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